<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04976283</url>
  </required_header>
  <id_info>
    <org_study_id>AKUH-GTZ-DM-005-21</org_study_id>
    <nct_id>NCT04976283</nct_id>
  </id_info>
  <brief_title>Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver</brief_title>
  <official_title>Which Oral Combination of Anti-diabetes Medication May Work Better in Subjects With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: a Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Getz Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Getz Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized clinical trial aims to compare the effect of the pioglitazone and SGLT2&#xD;
      inhibitor combination on liver fat mass, as compared to either drug used alone, with or&#xD;
      without background medical therapy of metformin and/or DDP4 inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the effect of pioglitazone with or without Metformin and/or DPP4 inhibitor (no&#xD;
      SGLT2 inhibitor) on improvement of NAFLD parameters, versus&#xD;
&#xD;
      The effect of SGLT inhibitor with or without metformin and/or DPP4 inhibitor (no&#xD;
      pioglitazone) on NAFLD parameters and versus&#xD;
&#xD;
      Pioglitazone with or without metformin and/or DPP4 inhibitor, plus empagliflozin on&#xD;
      improvement of NAFLD parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in radiologic liver parameters</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants reported change in liver fat content from baseline, as quantified by fibroscan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in liver enzymes</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants reported change in liver enzymes levels including ALT, AST and GGT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fibrosis-4 (FIB-4) Score and NAFLD Fibrosis Score</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants reported change in FIB-4 Score and NAFLD Fibrosis Score. Fibrosis-4 scores range from 0 to 4, where &lt;1.45 indicates absence of cirrhosis; score between 1.45 - 3.25 are deemed inconclusive and score &gt;3.25 indicates cirrhosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants reported change in body weight from baseline (treat to target response of at least 5% of baseline at 6 months, 10% baseline over 12 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference (WC)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants reported change in waist circumference (WC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in liver fat mass with total body fat (TBF)</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of baseline and end of treatment liver fat mass with total body fat (TBF) using a Body Composition Monitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1C levels (&lt; 7.0%)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants reported change in HbA1C levels from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Blood Sugar (FBS)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants reported change in Fasting Blood Sugar (FBS) from baseline to end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lipid profile</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants reported change in Fasting triglycerides (TG), Low-Density Lipoprotein (LDL), High-Density Lipoprotein (HDL) from baseline to end of treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Urine Albumin to Creatinine Ratio (UACR)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants reported change in Urine Albumin to Creatinine Ratio (UACR) from baseline to end of treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Systolic and Diastolic blood pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants reported change in Systolic and Diastolic blood pressure from baseline to end of treatment</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">123</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The starting dose would be 15mg/day for pioglitazone and 500 to 1500mg per day for metformin (depending on blood glucose levels). Starting dose for DPP4 inhibitors would be 50 to 100mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The starting dose would be 500-1500mg/day of metformin, plus 5/10/12.5mg empagliflozin (depending on blood glucose levels). Starting dose for DPP4 inhibitors would be 50 to 100mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone + Empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The starting dose would be 15mg/day for pioglitazone and 500 to1500mg per day for metformin and 5/10/12.5mg/25mg/day empagliflozin and 50 to 100mg daily for DPP4 inhibitors depending on blood sugar levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone with (or without) metformin and/or DPP4 inhibitor (no SGLT2 inhibitor). The maximum dose for metformin would be 2.5 g/day, while for pioglitazone would be 45mg/day. The maximum dose for DPP4 inhibitor would be 100mg/day.</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Zolid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Empagliflozin with (or without) metformin and/or DPP4 inhibitor (no pioglitazone). The maximum dose for metformin would be 2.5g/day, while for empagliflozin would be 25mg/day depending on follow up blood sugar levels and tolerability. The maximum dose 100mg daily.</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <other_name>Diampa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone + Empagliflozin</intervention_name>
    <description>Pioglitazone with (or without) metformin and/or DPP4 inhibitor, plus empagliflozin. The maximum dose for metformin would be 2.5g/day; for pioglitazone would be 45mg/day and 25mg/day for empagliflozin, and 100mg daily for DPP4 inhibitors (depending on follow up blood sugar levels and tolerability).</description>
    <arm_group_label>Pioglitazone + Empagliflozin</arm_group_label>
    <other_name>Zolid + Diampa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient who give informed consent voluntarily&#xD;
&#xD;
          -  Type 2 diabetic patient having age from 18 years to 60 years&#xD;
&#xD;
          -  HbA1C ≥ 7.0 %&#xD;
&#xD;
          -  Diabetes diagnosis of ≤ 5 years (longer duration more likely to be associated with use&#xD;
             of multiple drug regimens for glycemic control which may affect liver fat mass)&#xD;
&#xD;
          -  Either treatment naïve or on metformin alone or metformin/DPP4i combination&#xD;
&#xD;
          -  Absolute weight &lt; 100kg; BMI &lt; 45 (fibro scan machine cannot accommodate heavier&#xD;
             individuals)&#xD;
&#xD;
          -  Documented hepatosteatosis (If the fibroscan reveals S1 (mild fatty liver: 11-33%&#xD;
             fatty liver) to S3 (severe fatty liver: &gt; 67% fatty liver) liver fat&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hba1c ≥ 9% and/or blood sugar &gt; 250mg/dl&#xD;
&#xD;
          -  History of uncontrolled Endocrine disorder (for example uncontrolled hypothyroidism,&#xD;
             or that requiring frequent dose adjustment, or Cushings syndrome)&#xD;
&#xD;
          -  History of anti-obesity medication use within 3 months of consent for study enrollment&#xD;
             or weight loss procedure(bariatric surgery) within same duration&#xD;
&#xD;
          -  History of use of SGLT 2 inhibitors, glitazones, Glucagon-like peptide (GLP) 1&#xD;
             agonists 3 months prior to study enrollment as they influence liver fat&#xD;
&#xD;
          -  History of use of insulin/sulphonylurea 3 months prior to study enrollment owing to&#xD;
             weight gain and potential increase in liver fat conferred by these agents&#xD;
&#xD;
          -  History of vitamin E use (400mg twice daily) within 3 months of study enrollment&#xD;
&#xD;
          -  Drug induced liver disease or active substance abuse (cannabonnoid-derived substances&#xD;
             like heroin, cocaine, amphetamines) based on history and/or laboratory tests&#xD;
&#xD;
          -  Drugs known to be associated with hepatic steatosis like steroids, traditional&#xD;
             homeopathic medication (likely to contain steroids), methotrexate, valproate,&#xD;
             tamoxifen, amiodarone.&#xD;
&#xD;
          -  Alcohol use (History of alcoholism or a greater than recommended alcohol intake (&gt; 21&#xD;
             standard drinks on average per week in men and &gt; 14 standard drinks on average per&#xD;
             week in women)&#xD;
&#xD;
          -  Severe hepatic impairment (ALT levels &gt; 3 times upper limit normal)&#xD;
&#xD;
          -  Hepatitis B/C hepatitis (based on positive Hepatitis B surface antigen, Anti Hepatitis&#xD;
             C antibodies positive&#xD;
&#xD;
          -  Autoimmune hepatitis (in case of females), based on positive Anti-nuclear Antibody&#xD;
             (ANA) (homogenous, high titre)&#xD;
&#xD;
          -  Positive Human Immunodeficiency Virus ( HIV) test as this could influence liver&#xD;
             functions&#xD;
&#xD;
          -  Pregnant or lactating women/ plans for pregnancy over proceeding 13 months&#xD;
&#xD;
          -  Obstructive liver disease on the basis of laboratory and imaging studies&#xD;
&#xD;
          -  Chronic renal failure, or Glomerular Filtration Rate (GFR) &lt; 30 mls/minute (as&#xD;
             estimated by the MDRD equation)&#xD;
&#xD;
          -  Chronic heart failure, history of acute coronary artery disease or cerebrovascular&#xD;
             accident within 3 months of consent for study enrollment, based on history and/or&#xD;
             cardiac imaging&#xD;
&#xD;
          -  History of recurrent Urinary Tract Infections (UTI's) or mycotic infections&#xD;
&#xD;
          -  Presence of ketones on Urine Analysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Azra Rizwan, FCPS</last_name>
    <phone>+923212655271</phone>
    <email>azra.rizwan@aku.edu</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aga Khan University</investigator_affiliation>
    <investigator_full_name>Dr. Najmul Islam</investigator_full_name>
    <investigator_title>Professor Endocrinology, Diabetes</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

